Identification of epoxybergamottin as a CYP3A4 inhibitor in grapefruit peel
- 232 Downloads
The oral availability of many drugs metabolised by the enzyme cytochrome P 450 3A4 (CYP3A4) is increased if co-administered with grapefruit juice. Extracts from grapefruit peel have also demonstrated inhibitory activity and, during commercial manufacturing of grapefruit juice, inhibitory components might be squeezed into the juice from the peel. Thus, the aim of this in vitro study was to identify CYP3A4 inhibitors in grapefruit peel.
Grapefruit peel was extracted with diethyl ether, and the extract was further fractionated by normal-phase chromatography. Fractions demonstrating significant CYP3A4 inhibitory activity, as measured by the relative reduction in N-demethylation of diltiazem in transfected human liver epithelial cells, were subsequently separated by preparative thin-layer chromatography. Constituents of the fractions and isolated compounds were identified by nuclear magnetic resonance spectroscopy. Analysis of diltiazem and N-demethyl-diltiazem was performed using high-performance liquid chromatography.
Of the identified components in grapefruit peel, only epoxybergamottin demonstrated a concentration-dependent inhibition of the CYP3A4-mediated N-demethylation of diltiazem. The IC50 value was calculated to be 4.2±1.1 µM. Coumarins without the furan ring and flavonoids isolated from grapefruit peel did not interfere with the metabolism of diltiazem. The results indicated the presence of other CYP3A4 inhibitors in grapefruit peel, but these agents were lost during the purification process excluding their identification.
The furanocoumarin epoxybergamottin, present in grapefruit peel, is an inhibitor of CYP3A4. In commercial manufacturing of grapefruit juice, epoxybergamottin is possibly distributed into the juice. During manufacturing, however, epoxybergamottin may be hydrolysed to 6´,7´-dihydroxybergamottin, which has been suggested as an important CYP3A4 inhibitor in grapefruit juice.
KeywordsGrapefruit peel Furanocoumarins Epoxybergamottin
- 1.Josefsson M, Zackrisson AL, Ahlner J (1996) Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol 51:189–193Google Scholar
- 4.Soons PA, Vogels B, Roosemalen MCM, Schoemaker HC, Uchida E, Edgar B, Lundahl J, Cohen AF, Breimer DD (1991) Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther 50:394–403Google Scholar
- 5.Bailey DG, Arnold JMO, Strong HA, Munoz C, Spence JD (1993) Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 54:589–594Google Scholar
- 7.Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ (1995) Plasma-concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 58:127–131Google Scholar
- 11.Kantola T, Kivisto KT, Neuvonen PJ (1998) Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 63:397–402Google Scholar
- 12.Lilja JJ, Kivisto KT, Neuvonen PJ (1998) Grapefruit juice–simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 64:477–483Google Scholar
- 16.Scora RW, Kumamoto J, Soost RK, Nauer EM (1982) Contribution to the origin of the grapefruit, Citrus paradisi (Rutaceae). Syst Biol 7:170–177Google Scholar
- 17.Guo LQ, Fukuda K, Ohta T, Yamazoe Y (2000) Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 28:766–771Google Scholar
- 20.Bailey DG, Arnold JMO, Munoz C, Spence JD (1993) Grapefruit juice felodipine interaction—mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 53:637–642Google Scholar
- 24.Edwards DJ, Fitzsimmons ME, Schuetz EG, Yasuda K, Ducharme MP, Warbasse LH, Woster PM, Schuetz JD, Watkins P (1999) 6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 65:237–244Google Scholar
- 27.Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB (1997) Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents—decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 25:1228–1233PubMedGoogle Scholar
- 29.Pfeifer AMA, Cole KE, Smoot DT, Weston A, Groopman JD, Shields PG, Vignaud JM, Juillerat M, Lipsky MM, Trump BF, Lechner JF, Harris CC (1993) Simian virus-40 large tumor antigen-immortalized normal human liver epithelial-cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc Natl Acad Sci U S A 90:5123–5127PubMedGoogle Scholar
- 31.Molden E, Åsberg A, Christensen H (2000) CYP2D6 is involved in O-demethylation of diltiazem—an in vitro study with transfected human liver cells. Eur J Clin Pharmacol 56:575–579Google Scholar
- 34.Yamada Y, Nakatani N, Fuwa H (1987) Epoxyaurapten and marmin from juice oil in hassaku (Citrus hassaku) and the spasmolytic activity of 7-geranyloxycoumarin-related compounds. Agric Biol Chem 51:1105–1110Google Scholar
- 36.Imai F, Itoh K, Kishibuchi N, Kinoshita T, Sankawa U (1989) Constituents of the root bark of Murraya paniculata collected in Indonesia. Chem Pharm Bull 37:119–123Google Scholar
- 37.Kinoshita T, Wu JB, Ho FC (1996) Prenylcoumarins from Murraya paniculata var omphalocarpa (Rutaceae): the absolute configuration of sibiricin, mexoticin and omphamurin. Chem Pharm Bull 44:1208–1211Google Scholar